Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 33,151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Insomnia, Sleeplessness, Transient Insomnia
Interventions: Electric stimulation of the Vestibular Nerve - "VirtuSom", Electric stim of the Vestibular Nerve - "VirtuSom" - SHAM; Device
Lead sponsor: Philips Respironics; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 349 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Atlanta, Georgia • New York, New York • Rochester, New York + 2 more

Conditions: COPD
Interventions: Zofin, Placebo; Drug · Other
Lead sponsor: ZEO ScientifiX, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Asthma
Interventions: EPA enriched fish oils; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Mather, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Astegolimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 36
States / cities: Dothan, Alabama • Jasper, Alabama • Mobile, Alabama + 32 more

Conditions: Diabetes Mellitus, Type 2
Interventions: TT223 with Metformin and/or TZD, Placebo with Metformin and/or TZD; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Artesia, California • Los Angeles, California • Santa Ana, California + 17 more

Conditions: Amphetamine-Related Disorders
Interventions: Ondansetron; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 6
States / cities: Chula Vista, California • Costa Mesa, California • Honolulu, Hawaii + 3 more

Conditions: Frailty
Interventions: Metformin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 65 Years to 90 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, Placebo; Drug · Other
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 137
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 105 more

Conditions: Anxiety and Fear
Interventions: Interoceptive Aversive Memory Reactivation, Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil, Placebo Oil; Behavioral · Dietary Supplement
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Triple-Negative Breast Cancer
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Atezolizumab Placebo, Paclitaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 8
States / cities: Stanford, California • Fort Myers, Florida • St. Petersburg, Florida + 5 more

Conditions: Prostate Cancer Prevention
Interventions: SFN-rich broccoli sprout extract capsules, Gelatin capsule containing microcrystalline cellulose.; Drug · Dietary Supplement
Lead sponsor: Portland VA Medical Center; Federal
Eligibility: 21 Years and older · Male only
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: HIV-1 Infected Adults With Chronic HIV-1 Infection
Interventions: Arm A: Poly-ICLC, Arm B: Normal Saline; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Hip Fractures
Interventions: VK5211, Placebo; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Yorba Linda, California • Boynton Beach, Florida • Doral, Florida + 4 more

Conditions: Overactive Bladder Syndrome (OABS)
Interventions: Placebo, SMP-986; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 21
States / cities: Tuscon, Arizona • Atherton, California • San Bernadino, California + 18 more

Conditions: Bipolar Depression
Interventions: Palmitoylethanolamide (PEA), Placebo, Treatment as Usual (TAU); Drug
Lead sponsor: Rodrigo Machado-Vieira, MD, PhD, MSc; Other
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Wilmington, Delaware • Indianapolis, Indiana + 3 more

Conditions: Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Interventions: Efprezimod alfa, Methotrexate, Tacrolimus, Placebo; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: Social Anxiety, Social Anxiety Disorder
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Dapagliflozin placebo, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 38
States / cities: Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more

Conditions: Intermittent Claudication
Interventions: Metformin ER, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 35 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
Interventions: ARC1779 Injection, Placebo (normal saline); Drug
Lead sponsor: Archemix Corp.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Hackensack, New Jersey • Houston, Texas

Conditions: Type 2 Diabetes
Interventions: Placebo, Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC, Insulin Glargine 2.0 u/kg body wt SC; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Communicable Diseases, Infection, Anti-Infective Agents, Therapeutic Uses, Pharmacologic Actions
Interventions: Probiotic, Placebo; Dietary Supplement · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colon Cancer
Interventions: Vigil™ Vaccine, Placebo; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness

Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

Fish Oil to Prevent Asthma Exacerbations in Patients With ALOX5 Polymorphisms

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione

Ondansetron for the Treatment of Methamphetamine Dependence - 1

Metformin for Preventing Frailty in High-risk Older Adults

A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia

Impact of CBD-Rich Oil on Aversive Memory Reconsolidation

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation

Enhancement by Poly-ICLC During HIV-1 Infection

Acute Hip Fracture Study in Patients 65 Years or Greater

SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)

A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Cannabidiol to Reduce Anxiety Reactivity

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

Characteristics of Glargine in Type 2 Diabetics

Probiotics to Promote Intestinal Health

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases